Research and Markets: Gilenya (Fingolimod), Laquinimod and Cladribine - Impact on the Multiple Sclerosis (MS) Treatment La

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/969fc7/gilenya_fingolimo) has announced the addition of GlobalData's new report "Gilenya (Fingolimod), Laquinimod and Cladribine - Impact on the Multiple Sclerosis (MS) Treatment Landscape" to their offering.

Gilenya (Fingolimod), Laquinimod and Cladribine - Impact on the Multiple Sclerosis (MS) Treatment Landscape provides key information on current available treatment of Multiple Sclerosis, drivers and barriers for the future MS market and how the novel pipeline molecules will drive the global market

Scope

Data and information on the impact of Gilenya (Fingolimod), Laquinimod and Cladribine on the current treatment landscape of Multiple Sclerosis

Reasons to buy

Develop business strategies by understanding the trends and developments in Multiple Sclerosis market

Key Topics Covered:

1 Table of Contents 2 Summary

3 Multiple Sclerosis Overview

3.1 Disease Overview

3.2 Diagnosis

3.3 Epidemiology

4 Current Therapy Options

5 Unmet Need

6 Drivers and Barriers

6.1 Drivers

6.2 Barriers

7 Gilenya, Laquinimod and Cladribine - First Oral Therapies for Multiple Sclerosis

7.1 Gilenya Clinical Trial Details - TRANSFORMS and FREEDOMS

7.2 Laquinimod Clinical Trial Details - BRAVO and ALLEGRO

7.3 Cladribine - CLARITY, ONWARDS and ORACLE

8 Multiple Sclerosis Market

9 Appendix

For more information visit http://www.researchandmarkets.com/research/969fc7/gilenya_fingolimo.



CONTACT:

Research and Markets
Laura Wood, Senior Manager
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Professional Services  Other Professional Services

MEDIA:

Logo
 Logo

Suggested Articles

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."

F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization.

The deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies.